UP Man Urges Russia to Include His Stage-4 Cancer Son in Vaccine Trial; Know All About Enteromix

Russia Enteromix Cancer Vaccine: The Russian government is considering a humane request from a father to save the life of his 21-year-old son suffering from stage 4 cancer, to include him in vaccine trials. Manu Srivastava from Lucknow said when he got to know about the vaccine, he sent letters to Moscow. Srivastava has also written to the Indian government to help expedite the process and has been informed that his request is under consideration. "I requested them, since my son had stage four cancer here. He's being treated here, but the doctors haven't been fully responsive. I was worried as there was no certainty. So, when I learned that a vaccine had been developed in Russia, proving very effective in treating cancer, I sent letters to the Government

of India and the Russian government,” Srivastava told ANI. “The reply came back saying my request was under consideration and the Russian government had sent it to their Ministry of Health for further processing," he added.

#WATCH | Lucknow, Uttar Pradesh | A Lucknow Resident, Manu Srivastava's 21-year-old son is suffering from 4th-stage cancer. He had written a letter to Prime Minister Narendra Modi, Chief Minister of Uttar Pradesh Yogi Adityanath, Union Health Minister, as well as high officials… pic.twitter.com/BE2AWa2inI

— ANI (@ANI) November 15, 2025

Russia’s cancer vaccine

Russia is developing an mRNA-based cancer vaccine known as Enteromix - designed to train the immune system to recognize and destroy cancer cells. According to news reports, the vaccine uses a personalized approach, based on a genetic profile of a patient's tumour, and has shown promising results in initial trials for shrinking tumours and slowing their growth. The initial target is colorectal cancer, with future potential for other cancers like glioblastoma and melanoma.

Enteromax shows 100 per cent efficacy

In September, Russia announced Enteromix demonstrated 100 per cent efficacy and safety in initial human trials. According to media reports, the vaccine made patients experience tumour shrinkage and no serious side effects. Enteromix was born from years of coordinated research by Russia's National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology. The vaccine leverages mRNA technology, similar to the platform that enabled rapid COVID-19 vaccine development, to generate a custom immune response against cancer cells. The personalized nature of Enteromix means each dose is tailored to the individual's tumour genomics, a biomarker-driven approach enabled by sophisticated mutation-profiling algorithms. Unlike other conventional cancer vaccines, Enteromix is said to have a fully personalized design where every vial is crafted based on the genetic makeup of an individual's tumour, improving target specificity and immune engagement. Its mRNA platform allows rapid development and scalability, something decades-long efforts in cancer vaccines have lacked.